Latest News

physicians using TAVR
TAVR Clinical Trial Provides ‘Strong Signal’ Procedure is Safe for Patients with Low Surgical Mortality Risk
Patients Undergoing Transcatheter Aortic Valve Replacement Showed No Deaths or Disabling Strokes within 30 days of Undergoing Less Invasive Procedure



Tags : aortic stenosis , Low-Risk TAVR trial , MedStar Heart & Vascular Institute , TAVR ,

Edward Y. Woo Named Head of MedStar Regional Vascular Surgery Program
Renowned vascular surgeon, Edward Y. Woo, MD, FACS, has been named director of the MedStar Regional Vascular Surgery Program, headquartered at MedStar Washington Hospital Center.